Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 179

    1.

    Expression patterns and prognostic value of Bag-1 and Bcl-2 in breast cancer.

    Nadler Y, Camp RL, Giltnane JM, Moeder C, Rimm DL, Kluger HM, Kluger Y.

    Breast Cancer Res. 2008;10(2):R35. Epub 2008 Apr 23.

    PMID:
    18430249
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    2.

    Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast.

    von Minckwitz G, Sinn HP, Raab G, Loibl S, Blohmer JU, Eidtmann H, Hilfrich J, Merkle E, Jackisch C, Costa SD, Caputo A, Kaufmann M; German Breast Group.

    Breast Cancer Res. 2008;10(2):R30. Epub 2008 Apr 1.

    PMID:
    18380893
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    3.

    BAG-1 expression correlates with Bcl-2, p53, differentiation, estrogen and progesterone receptors in invasive breast carcinoma.

    Tang SC, Beck J, Murphy S, Chernenko G, Robb D, Watson P, Khalifa M.

    Breast Cancer Res Treat. 2004 Apr;84(3):203-13.

    PMID:
    15026618
    [PubMed - indexed for MEDLINE]
    4.

    Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes.

    Habibi G, Leung S, Law JH, Gelmon K, Masoudi H, Turbin D, Pollak M, Nielsen TO, Huntsman D, Dunn SE.

    Breast Cancer Res. 2008;10(5):R86. Epub 2008 Oct 16.

    PMID:
    18925950
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    5.

    Can expression of apoptosis genes, bcl-2 and bax, predict survival and responsiveness to chemotherapy in node-negative breast cancer patients?

    Kymionis GD, Dimitrakakis CE, Konstadoulakis MM, Arzimanoglou I, Leandros E, Chalkiadakis G, Keramopoulos A, Michalas S.

    J Surg Res. 2001 Aug;99(2):161-8.

    PMID:
    11469882
    [PubMed - indexed for MEDLINE]
    6.

    Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.

    Lee KH, Im SA, Oh DY, Lee SH, Chie EK, Han W, Kim DW, Kim TY, Park IA, Noh DY, Heo DS, Ha SW, Bang YJ.

    BMC Cancer. 2007 Apr 12;7:63.

    PMID:
    17430582
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    7.

    High HSP90 expression is associated with decreased survival in breast cancer.

    Pick E, Kluger Y, Giltnane JM, Moeder C, Camp RL, Rimm DL, Kluger HM.

    Cancer Res. 2007 Apr 1;67(7):2932-7.

    PMID:
    17409397
    [PubMed - indexed for MEDLINE]
    Free Article
    8.

    A divergent role for estrogen receptor-beta in node-positive and node-negative breast cancer classified according to molecular subtypes: an observational prospective study.

    Novelli F, Milella M, Melucci E, Di Benedetto A, Sperduti I, Perrone-Donnorso R, Perracchio L, Venturo I, Nisticò C, Fabi A, Buglioni S, Natali PG, Mottolese M.

    Breast Cancer Res. 2008;10(5):R74. Epub 2008 Sep 4.

    PMID:
    18771580
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    9.

    Immunohistochemical biomarkers in patients with early-onset breast carcinoma by tissue microarray.

    Choi DH, Kim S, Rimm DL, Carter D, Haffty BG.

    Cancer J. 2005 Sep-Oct;11(5):404-11.

    PMID:
    16259871
    [PubMed - indexed for MEDLINE]
    10.

    Lower level of MAPK expression is associated with anthracycline resistance and decreased survival in patients with hormone receptor negative breast cancer.

    Derin D, Eralp Y, Ozluk Y, Yavuz E, Guney N, Saip P, Igci A, Ozmen V, Kücücük S, Aslay I, Aydiner A, Topuz E.

    Cancer Invest. 2008 Aug;26(7):671-9.

    PMID:
    18608215
    [PubMed - indexed for MEDLINE]
    11.

    Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.

    Martín M, Rodríguez-Lescure A, Ruiz A, Alba E, Calvo L, Ruiz-Borrego M, Munárriz B, Rodríguez CA, Crespo C, de Alava E, López García-Asenjo JA, Guitián MD, Almenar S, González-Palacios JF, Vera F, Palacios J, Ramos M, Gracia Marco JM, Lluch A, Alvarez I, Seguí MA, Mayordomo JI, Antón A, Baena JM, Plazaola A, Modolell A, Pelegrí A, Mel JR, Aranda E, Adrover E, Alvarez JV, García Puche JL, Sánchez-Rovira P, Gonzalez S, López-Vega JM; GEICAM 9906 Study Investigators.

    J Natl Cancer Inst. 2008 Jun 4;100(11):805-14. Epub 2008 May 27.

    PMID:
    18505968
    [PubMed - indexed for MEDLINE]
    Free Article
    12.

    Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma.

    Bos R, van der Groep P, Greijer AE, Shvarts A, Meijer S, Pinedo HM, Semenza GL, van Diest PJ, van der Wall E.

    Cancer. 2003 Mar 15;97(6):1573-81.

    PMID:
    12627523
    [PubMed - indexed for MEDLINE]
    Free Article
    13.

    Multivariate analysis of bcl-2, apoptosis, P53 and HER-2/neu in breast cancer: a short-term follow-up.

    el-Ahmady O, el-Salahy E, Mahmoud M, Wahab MA, Eissa S, Khalifa A.

    Anticancer Res. 2002 Jul-Aug;22(4):2493-9.

    PMID:
    12174951
    [PubMed - indexed for MEDLINE]
    14.

    Insulin receptor is an independent predictor of a favorable outcome in early stage breast cancer.

    Mulligan AM, O'Malley FP, Ennis M, Fantus IG, Goodwin PJ.

    Breast Cancer Res Treat. 2007 Nov;106(1):39-47. Epub 2007 Jan 13.

    PMID:
    17221153
    [PubMed - indexed for MEDLINE]
    15.

    Stromal CD10 expression in invasive breast carcinoma correlates with poor prognosis, estrogen receptor negativity, and high grade.

    Makretsov NA, Hayes M, Carter BA, Dabiri S, Gilks CB, Huntsman DG.

    Mod Pathol. 2007 Jan;20(1):84-9. Epub 2006 Nov 24.

    PMID:
    17143263
    [PubMed - indexed for MEDLINE]
    Free Article
    16.

    Expression of BAG-1 and BcL-2 proteins before and after neoadjuvant chemotherapy of locally advanced breast cancer.

    Pusztai L, Krishnamurti S, Perez Cardona J, Sneige N, Esteva FJ, Volchenok M, Breitenfelder P, Kau SW, Takayama S, Krajewski S, Reed JC, Bast RC Jr, Hortobagyi GN.

    Cancer Invest. 2004;22(2):248-56.

    PMID:
    15199607
    [PubMed - indexed for MEDLINE]
    17.

    Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.

    Gasparini G, Barbareschi M, Doglioni C, Palma PD, Mauri FA, Boracchi P, Bevilacqua P, Caffo O, Morelli L, Verderio P, et al.

    Clin Cancer Res. 1995 Feb;1(2):189-98.

    PMID:
    9815973
    [PubMed - indexed for MEDLINE]
    Free Article
    18.

    Factors predictive of response to hormone therapy in breast cancer.

    Rastelli F, Crispino S.

    Tumori. 2008 May-Jun;94(3):370-83. Review.

    PMID:
    18705406
    [PubMed - indexed for MEDLINE]
    19.

    Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer.

    Osborne CK, Bardou V, Hopp TA, Chamness GC, Hilsenbeck SG, Fuqua SA, Wong J, Allred DC, Clark GM, Schiff R.

    J Natl Cancer Inst. 2003 Mar 5;95(5):353-61.

    PMID:
    12618500
    [PubMed - indexed for MEDLINE]
    Free Article
    20.

    Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.

    Pentheroudakis G, Kalogeras KT, Wirtz RM, Grimani I, Zografos G, Gogas H, Stropp U, Pectasides D, Skarlos D, Hennig G, Samantas E, Bafaloukos D, Papakostas P, Kalofonos HP, Pavlidis N, Fountzilas G.

    Breast Cancer Res Treat. 2009 Jul;116(1):131-43. Epub 2008 Jul 31.

    PMID:
    18668363
    [PubMed - indexed for MEDLINE]

      Display Settings:

      Format
      Items per page
      Sort by

      Send to:

      Choose Destination

      Supplemental Content

      Find related data

      Write to the Help Desk